Glaxo Bid Undervalues Human Genome Sciences, Sunday Times Says

GlaxoSmithKline Plc’s $2.6 billion offer for Human Genome Sciences Inc. “completely undervalues” the company according to a major shareholder, the Sunday Times reported.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.